Journal of Clinical Psychopharmacology最新文献

{"title":"Xanomeline/Trospium Chloride as an Adjunctive Treatment for a Patient With Treatment-Resistant Schizoaffective Disorder: A Case Report of Unanticipated Side Effects.","authors":"Esther Y Son, Trevar K Ziemer, Danielle L Anderson","doi":"10.1097/JCP.0000000000002153","DOIUrl":"10.1097/JCP.0000000000002153","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"347-348"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human Abuse Potential of Single Oral Doses of Sunobinop, a Novel, Highly Potent, and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors.","authors":"Stephen C Harris, Alessandra Cipriano, Garth T Whiteside, Kerri A Schoedel, Ellie He, Manjunath S Shet, Glen Apseloff","doi":"10.1097/JCP.0000000000002147","DOIUrl":"10.1097/JCP.0000000000002147","url":null,"abstract":"<p><strong>Background: </strong>Sunobinop is a selective, partial agonist of the nociceptin/orphanin FQ peptide receptor and has multiple potential indications, including insomnia, bladder disorders, and alcohol use disorder. The purpose of this study was to examine the abuse potential and pharmacodynamic effects of sunobinop compared with triazolam in healthy adults with a history of nonmedical use of central nervous system drugs with depressant/sedative properties.</p><p><strong>Methods: </strong>This was a single-dose, randomized, double-blind, double-dummy, placebo-controlled and positive-controlled crossover study. Each participant received 6 treatments: sunobinop 1 mg, 6 mg, and 10 mg plus triazolam placebo, sunobinop placebo plus triazolam 0.5 mg and 1 mg, and sunobinop placebo plus triazolam placebo. The primary endpoint for the treatment phase was \"at this moment\" drug-liking visual analog scale (VAS) maximum effect (0 to 100).</p><p><strong>Results: </strong>Fifty participants completed the study. The mean \"at this moment\" drug-liking VAS scores for sunobinop 1 mg remained within the neutral range (40 to 60) with a peak score of 54.1 and comparable with placebo at all time points. In contrast, \"at this moment\" drug-liking VAS scores for triazolam control doses increased over time, peaking ∼2 hours following dosing at a mean score of 65.0 and 63.4 for triazolam 0.5 mg and 1.0 mg, respectively.</p><p><strong>Conclusions: </strong>Drug-liking following sunobinop at a potential therapeutic dose was not different from placebo and was significantly lower compared with triazolam at a recommended dose. In addition, its good tolerability profile suggests sunobinop may be a useful new treatment option, particularly in at-risk populations.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"297-310"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13105734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147499289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of Intranasal Esketamine Administration in Brugada Syndrome: Two Clinical Case Reports.","authors":"Aurélie Bobet, Antoine Yrondi, Anne Rollin, Racan Abidine, François Montastruc, Tanguy Taillefer de Laportaliere","doi":"10.1097/JCP.0000000000002144","DOIUrl":"10.1097/JCP.0000000000002144","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"342-344"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147344494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravenous Continuous Infusion of Dexmedetomidine for Psychomotor Agitation in General Hospital Psychiatric Settings: A Transdiagnostic Case Series.","authors":"Arthur Tolentino, Felipe Mendonça Rocha Barros, Ana Laura Schumacher, Rafael Robles, Angelo Samuelson, Barbara Colnaghi, Eduardo Prado Barreto, Fernando Resende, Liliane Smaniotto, Lucas Barnes, Leandro Schlittler, Karina Diniz Oliveira, Amilton Dos Santos Junior, Claudio E M Banzato, Osmar Della-Torre","doi":"10.1097/JCP.0000000000002097","DOIUrl":"10.1097/JCP.0000000000002097","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"359-362"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perinatal Safety of Quetiapine During Pregnancy: A Systematic Review, Meta-Analysis, ‎‎and ‎Evidence Gaps.","authors":"Ghada M Alem, Sarah Fatani, Saad A Aldosari, Nehad Ahmed, Marwa Balaha, Mohamed F Balaha","doi":"10.1097/JCP.0000000000002127","DOIUrl":"10.1097/JCP.0000000000002127","url":null,"abstract":"<p><strong>Purpose: </strong>The reproductive safety profiles of quetiapine (QTP) during pregnancy are not fully understood. This review primarily assesses perinatal outcomes and major malformations following exposure to quetiapine.</p><p><strong>Methods: </strong>‎A comprehensive literature search identified 33 studies published through February 2025. Outcomes were synthesized for QTP using random-effects models and benchmarked against population surveillance and psychiatric controls when available.</p><p><strong>Results: </strong>‎Among 13,090 pregnancies exposed to QTP with malformation outcomes, the major malformation rate was 4.1%, which is comparable to background rates. Perinatal outcomes were similar to those of the controls for QTP. Several high-quality studies have shown a dose-response relationship between higher QTP doses and the risk of gestational diabetes.</p><p><strong>Conclusions: </strong>QTP is not associated with an increased risk of major malformations and does not significantly raise adverse perinatal outcomes compared with controls. The dose-related metabolic risks of QTP underscore the importance of minimizing dosage and closely monitoring metabolism during pregnancy.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"322-337"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146085945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutropenia Associated With Trazodone: A Rare Case.","authors":"Sen Zhang, Fan-Cui Meng, Ya-Hui Xu, Hua Ouyang, Qi-Meng Sun","doi":"10.1097/JCP.0000000000002150","DOIUrl":"10.1097/JCP.0000000000002150","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"354-356"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147283930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Higher Neutrophil-to-Lymphocyte Ratio Is Associated With Better Response to Esketamine in Treatment-Resistant Depression: A Post Hoc Exploratory Analysis of Real-World Data.","authors":"Matteo Carminati, Mattia Tondello, Chiara Morana, Michele Prato, Raffaella Zanardi","doi":"10.1097/JCP.0000000000002190","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002190","url":null,"abstract":"<p><strong>Background: </strong>Growing evidence links inflammation with major depressive disorder (MDD) and treatment resistance. The neutrophil-to-lymphocyte ratio (NLR) has emerged as a simple peripheral marker of systemic inflammation and immune balance and it may capture clinically meaningful heterogeneity in inflammatory burden, potentially contributing to variability in antidepressant response and vulnerability to treatment resistance. This study exploratively investigated whether baseline NLR values are associated with clinical response in patients with treatment-resistant depression (TRD) treated with intranasal esketamine in routine clinical practice.</p><p><strong>Methods: </strong>This retrospective observational study included patients with TRD treated with adjunctive intranasal esketamine at the Mood Disorder Unit of San Raffaele Hospital (Milan, Italy). Baseline NLR was calculated from complete blood count samples collected 1 to 7 days before treatment initiation. Clinical outcome was assessed after 7 months using the Clinical Global Impression-Improvement scale (CGI-I). Patients were classified as responders (CGI-I ≤2) or non-responders (CGI-I ≥3). An analysis of covariance (ANCOVA) was conducted to examine differences in baseline NLR while adjusting for age.</p><p><strong>Results: </strong>The final sample included 16 patients (8 responders and 8 non-responders). Responders showed higher baseline NLR values compared with non-responders (1.81±0.81 vs. 1.23±0.29). After controlling for age, baseline NLR differed significantly between the 2 outcome groups (P=0.003).</p><p><strong>Conclusions: </strong>Higher baseline NLR was associated with sustained clinical improvement after 6 months of esketamine treatment in patients with TRD. Although preliminary and limited by the small sample size and retrospective design, these findings suggest that a patient's inflammatory status at baseline may affect their treatment response. Larger prospective studies are needed to clarify the role of inflammatory markers as predictors of response to esketamine.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147815664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prolonged QTc Interval Normalization After Switch to Lurasidone: A Case Series.","authors":"Daisuke Takeuchi, Naoto Omata, Junichi Murayama","doi":"10.1097/JCP.0000000000002157","DOIUrl":"10.1097/JCP.0000000000002157","url":null,"abstract":"<p><strong>Background: </strong>QTc prolongation is a known side effect of antipsychotics and antidepressants and can lead to torsade de pointes, a potentially fatal tachycardia that may result in sudden death. Lurasidone is an atypical antipsychotic associated with a low incidence of QTc prolongation. However, the effect of switching to lurasidone after antipsychotic- or antidepressant-induced QTc prolongation remains underexplored.</p><p><strong>Procedures: </strong>Nine inpatients with prolonged QTc intervals following treatment with various antipsychotics or antidepressants were included. QTc intervals were compared before and after switching to lurasidone.</p><p><strong>Findings: </strong>Most patients exhibited shorter QTc intervals after switching to lurasidone.</p><p><strong>Implications/conclusions: </strong>This case series demonstrated that switching to lurasidone reduced QTc prolongation induced by other antipsychotics or antidepressants. Lurasidone may lower the risk of sudden cardiac death in patients with psychiatric disorders by shortening QTc intervals.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"320-321"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147283922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase 2b Trial of the PDE10A Inhibitor MK-8189 in People With an Acute Episode of Schizophrenia.","authors":"Yuki Mukai, James Kost, Linda Snow-Adami, Jessica Reed, Theresa Taylor, Justine Kent, Michael F Egan","doi":"10.1097/JCP.0000000000002152","DOIUrl":"10.1097/JCP.0000000000002152","url":null,"abstract":"<p><strong>Background: </strong>PDE10A inhibition represents a potential mechanism for treating schizophrenia. A 12-mg dose of the PDE10A inhibitor MK-8189 showed initial evidence of efficacy for improving schizophrenia symptoms after 4 weeks. We performed a follow-up study evaluating higher MK-8189 doses (16 mg and 24 mg, predicted to produce up to 80% sustained enzyme occupancy) over 6 weeks.</p><p><strong>Methods: </strong>Randomized, double-blind, phase 2b study consisting of a 6-week acute treatment period and a 6-week extension (NCT04624243). Participants were diagnosed with schizophrenia and were experiencing active phase symptoms. For the acute treatment period, participants were randomized in a 2:2:2:1:2 ratio to 6 weeks of daily MK-8189 8 mg (dropped after a third of participants had been enrolled), 16 mg, 24 mg, risperidone 6 mg (for assay sensitivity), or placebo. The primary outcome was the change from baseline in Positive and Negative Syndrome Scale (PANSS) total score at 6 weeks.</p><p><strong>Results: </strong>The number of treated participants in the acute period was: MK-8189 16 mg, N=132; MK-8189 24 mg, N=132; risperidone 6 mg, N=65; and placebo, N=129. MK-8189 16 mg and 24 mg did not show an improvement versus placebo for change-from-baseline in PANSS total score after 6 weeks [16 mg-placebo difference, -2.8 (95% CI: -8.3,2.6), P =0.241; 24 mg-placebo difference, -0.7 (95% CI: -6.3,4.9), P =0.784], whereas risperidone did [risperidone-placebo difference, -6.2 (95% CI: -12.9,0.6), P =0.040]. Over the 6-week acute period, more participants discontinued treatment due to an adverse event in the MK-8189 24 mg group (25.0%) than in the MK-8189 16 mg (12.9%), risperidone (12.3%) or placebo (12.4%) groups.</p><p><strong>Conclusions: </strong>These findings suggest that PDE10A inhibition does not have antipsychotic effects at the doses tested.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"311-319"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13105519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147271081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Adjuvant GLP-1RA Treatment on the Adherence of Second-Generation Antipsychotics in Nondiabetic Adults.","authors":"Jerusha Daggolu, Michael Okonkwo, Hua Chen","doi":"10.1097/JCP.0000000000002145","DOIUrl":"10.1097/JCP.0000000000002145","url":null,"abstract":"<p><strong>Background: </strong>Second-generation antipsychotics (SGA) are well known to frequently cause weight gain, increasing cardiometabolic risk, and reducing medication adherence. Glucagon-like peptide-1 receptor agonists (GLP-1RA) mitigate weight gain in controlled settings, but their real-world impact on SGA adherence remains unexplored. This study evaluated the role of adjuvant GLP-1RA treatment in improving SGA adherence among nondiabetic adults.</p><p><strong>Methods: </strong>A retrospective cohort study using the MarketScan Commercial and Medicaid claims database (2019-2023) identified nondiabetic adult patients initiating GLP-1RA following an SGA prescription, with ≥60 days overlap between SGA and GLP-1RA prescription fills (Adjuvant GLP-1RA users). Eligible patients were continuously enrolled 90 days pre-GLP-1RA and 180 days post-GLP-1RA initiation (index date). Prescription-time-distribution matching addressed immortal time bias and assigned an index date to SGA-only users. Propensity score matching (PSM) adjusted for baseline covariates.</p><p><strong>Results: </strong>This study identified 2153 eligible patients in the commercial and 787 in the Medicaid subgroups. Compared with SGA-only users, adjuvant GLP-1-RA users achieved a higher mean proportion of days covered (PDC; 74.30% vs 66.91%) and longer persistence (165.6 vs 139.2 d). Medicaid patients showed similar benefits (PDC: 88.25% vs 70.32%; persistence: 162.1 vs 122.1 d). PSM adjusted models demonstrated that the difference in PDC between the study groups was 8.91% (commercial) and 19.80% (Medicaid), with corresponding differences in persistence of 27.12 and 41.21 days. The effect was consistent both when the follow-up period was extended to 365 days and when examined across individual GLP-1RA agents.</p><p><strong>Conclusions: </strong>Adjuvant GLP-1RA is associated with improved PDC and adherence to SGA in nondiabetic adults.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"289-296"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146165715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}